Comparison of presenting clinical and laboratory findings between patients with therapy-related (t-AML) and de novo AML
Characteristic . | t-AML . | de novo AML . | P . |
---|---|---|---|
Patients, no. (%) | 200 (7.0) | 2653 (93.0) | |
Sex, male/female, no. (%) | 64 (32)/136 (68) | 1409 (53)/1244 (47) | < .0001 |
Median age, y (range) | 57.8 (18.6-79.4) | 53.2 (16.2-85.0) | < .0001 |
WBC, × 109/L | .003 | ||
Median | 7.4 | 12.5 | |
Range | 0.4-258 | 0.1-527 | |
Missing | 51 | 58 | |
Hemoglobin, g/dL | .04 | ||
Median | 9.4 | 9.1 | |
Range | 4.2-13.7 | 2.5-20.6 | |
Missing | 1 | 60 | |
Platelet count, × 109/L | .02 | ||
Median | 50.5 | 55 | |
Range | 2-595 | 4-933 | |
Missing | 2 | 60 | |
PB blasts, % | .002 | ||
Median | 22 | 35 | |
Range | 0-100 | 0-100 | |
Missing | 20 | 244 | |
BM blasts, % | .03 | ||
Median | 65 | 75 | |
Range | 2-100 | 0-100 | |
Missing | 17 | 246 | |
LDH value, U/L | .09 | ||
Median | 372 | 413 | |
Range | 90-15 098 | 40-7627 | |
Missing | 8 | 108 |
Characteristic . | t-AML . | de novo AML . | P . |
---|---|---|---|
Patients, no. (%) | 200 (7.0) | 2653 (93.0) | |
Sex, male/female, no. (%) | 64 (32)/136 (68) | 1409 (53)/1244 (47) | < .0001 |
Median age, y (range) | 57.8 (18.6-79.4) | 53.2 (16.2-85.0) | < .0001 |
WBC, × 109/L | .003 | ||
Median | 7.4 | 12.5 | |
Range | 0.4-258 | 0.1-527 | |
Missing | 51 | 58 | |
Hemoglobin, g/dL | .04 | ||
Median | 9.4 | 9.1 | |
Range | 4.2-13.7 | 2.5-20.6 | |
Missing | 1 | 60 | |
Platelet count, × 109/L | .02 | ||
Median | 50.5 | 55 | |
Range | 2-595 | 4-933 | |
Missing | 2 | 60 | |
PB blasts, % | .002 | ||
Median | 22 | 35 | |
Range | 0-100 | 0-100 | |
Missing | 20 | 244 | |
BM blasts, % | .03 | ||
Median | 65 | 75 | |
Range | 2-100 | 0-100 | |
Missing | 17 | 246 | |
LDH value, U/L | .09 | ||
Median | 372 | 413 | |
Range | 90-15 098 | 40-7627 | |
Missing | 8 | 108 |
Percentages may not add to 100 because of rounding.
AML indicates acute myeloid leukemia; BM, bone marrow; LDH, serum lactate dehydrogenase; PB, peripheral blood; and WBC, white blood count.